Clinical Trial Update: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-8591A-019 evaluating the Doravirine/Islatravir combination in heavily treatment-experienced HIV-1 infection reported results with data posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine (doravirine)
• Islatravir (Islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2023-12-08